Author Correction: Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance (Nature Medicine, (2017), 23, 5, (556-567), 10.1038/nm.4314);Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

Nature Medicine

Volumn 23, Issue 5, 2017, Pages 556-567

  Daley, Donnele ^a   Mani, Vishnu R ^a   Mohan, Navyatha ^a   Akkad, Neha ^a   Ochi, Atsuo ^a   Heindel, Daniel W ^b   Lee, Ki Buom ^a   Zambirinis, Constantinos P ^a   Pandian, Gautam S D Balasubramania ^a   Savadkar, Shivraj ^a   Torres Hernandez, Alejandro ^a   Nayak, Shruti ^a   Wang, Ding ^a   Hundeyin, Mautin ^a   Diskin, Brian ^a   Aykut, Berk ^a   Werba, Gregor ^a   Barilla, Rocky M ^a   Rodriguez, Robert ^a   Chang, Steven ^b   Gardner, Lawrence ^a   Mahal, Lara K ^b   Ueberheide, Beatrix ^a   Miller, George ^a   more..

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DECTIN 1; ECALECTIN; GALECTIN; GALECTIN 9, MOUSE; LECTIN; LGALS9 PROTEIN, HUMAN; PROTEIN KINASE SYK;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; CYTOLOGY; FLOW CYTOMETRY; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; MASS SPECTROMETRY; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PANCREATIC DUCT; TUMOR ESCAPE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; EPITHELIAL CELLS; FLOW CYTOMETRY; GALECTINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LECTINS, C-TYPE; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; SYK KINASE; TUMOR ESCAPE;

EID: 85017279150     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-021-01428-0     Document Type: Erratum

References (47)

1. Yadav, D. & Lowenfels, A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144, 1252-1261 (2013).
2. Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302 (2007).
3. Ochi, A. et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 209, 1671-1687 (2012).
4. Zhu, Y. et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057-5069 (2014).
5. Connolly, M. K. et al. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J. Leukoc. Biol. 87, 713-725 (2010).
6. Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836-847 (2012).
7. Bayne, L. J. et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21, 822-835 (2012).
8. Goodridge, H. S. et al. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature 472, 471-475 (2011).
9. Taylor, P. R. et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat. Immunol. 8, 31-38 (2007).
10. Strasser, D. et al. Syk kinase-coupled C-type lectin receptors engage protein kinase C-to elicit Card9 adaptor-mediated innate immunity. Immunity 36, 32-42 (2012).
11. Gross, O. et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442, 651-656 (2006).
12. Seifert, L. et al. Dectin-1 regulates hepatic fibrosis and hepatocarcinogenesis by suppressing TLR4 signaling pathways. Cell Rep. 13, 1909-1921 (2015).
13. Seifert, L. et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532, 245-249 (2016).
14. Zambirinis, C. P. et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J. Exp. Med. 212, 2077-2094 (2015).
15. Ochi, A. et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J. Clin. Invest. 122, 4118-4129 (2012).
16. Walachowski, S., Tabouret, G. & Foucras, G. Triggering dectin-1-pathway alone is not sufficient to induce cytokine production by murine macrophages. PLoS One 11, e0148464 (2016).
17. Zheng, L., Xue, J., Jaffee, E. M. & Habtezion, A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 144, 1230-1240 (2013).
18. Clark, C. E. et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518-9527 (2007).
19. Andrén-Sandberg, A., Dervenis, C. & Lowenfels, B. Etiologic links between chronic pancreatitis and pancreatic cancer. Scand. J. Gastroenterol. 32, 97-103 (1997).
20. Fukunaga, A. et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28, e26-e31 (2004).
21. De Monte, L. et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208, 469-478 (2011).
22. Hiraoka, N., Onozato, K., Kosuge, T. & Hirohashi, S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12, 5423-5434 (2006).
23. Jiang, Y. et al. FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis. PLoS One 9, e106741 (2014).
24. Vautier, S., MacCallum, D. M. & Brown, G. D. C-type lectin receptors and cytokines in fungal immunity. Cytokine 58, 89-99 (2012).
25. Ferwerda, B. et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361, 1760-1767 (2009).
26. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1-5 (2007).
27. Chiba, S. et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. eLife 3, e04177 (2014).
28. Hong, F. et al. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173, 797-806 (2004).
29. Yamasaki, S. et al. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat. Immunol. 9, 1179-1188 (2008).
30. Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245-1252 (2005).
31. Anderson, A. C. et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318, 1141-1143 (2007).
32. Leitner, J. et al. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog. 9, e1003253 (2013).
33. Madireddi, S. et al. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J. Exp. Med. 211, 1433-1448 (2014).
34. Martínez-Bosch, N. et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res. 74, 3512-3524 (2014).
35. Banh, A. et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 71, 4423-4431 (2011).
36. Rubinstein, N. et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5, 241-251 (2004).
37. Demotte, N. et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70, 7476-7488 (2010).
38. Nobumoto, A. et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18, 735-744 (2008).
39. Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402-1410 (2016).
40. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
41. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
42. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
43. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
44. Daley, D. et al. T cells support pancreatic oncogenesis by restraining T cell activation. Cell 166, 1485-1499. e15 (2016).
45. Bedrosian, A. S. et al. Dendritic cells promote pancreatic viability in mice with acute pancreatitis. Gastroenterology 141, 1915-1926 (2011).
46. Greco, S. H. et al. Mincle suppresses Toll-like receptor 4 activation. J. Leukoc. Biol. 100, 185-194 (2016).
47. Hruban, R. H. et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579-586 (2001).